Table 1. Association therapy of CFI-400945 with DNA-damaging drugs as determined by a viability assay.
| Cell Line | Compound 1 | Compound 2 | IC50 of compound 2 (μM) | Standard deviation compound 2 | P value* |
|---|---|---|---|---|---|
| MON | Doxorubicin | 0.134 | 0.01713 | ||
| MON | CFI-400945 (5nM) | Doxorubicin | 0.074 | 0.00125 | 0.0631 |
| MON | CFI-400945 (10nM) | Doxorubicin | 0.057 | 0.00806 | 0.0386 |
| MON | Etoposide | 0.967 | 0.00668 | ||
| MON | CFI-400945 (5nM) | Etoposide | 0.292 | 0.01590 | 0.0902 |
| MON | CFI-400945 (10nM) | Etoposide | 0.266 | 0.00290 | 0.0010 |
| BT-16 | Doxorubicin | 1.429 | 0.00806 | ||
| BT-16 | CFI-400945 (5nM) | Doxorubicin | 0.566 | 0.00450 | 0.0118 |
| BT-16 | CFI-400945 (10nM) | Doxorubicin | 0.576 | 0.00650 | 0.0213 |
| BT-16 | Etoposide | 0.800 | 0.02269 | ||
| BT-16 | CFI-400945 (5nM) | Etoposide | 0.593 | 0.01034 | 0.0743 |
| BT-16 | CFI-400945 (10nM) | Etoposide | 0.006 | 0.00873 | 0.0002 |
| DAOY | Doxorubicin | 0.263 | 0.01178 | ||
| DAOY | CFI-400945 (5nM) | Doxorubicin | 0.168 | 0.00309 | 0.0198 |
| DAOY | CFI-400945 (10nM) | Doxorubicin | 0.199 | 0.00356 | 0.0573 |
| DAOY | Etoposide | 0.495 | 0.01296 | ||
| DAOY | CFI-400945 (5nM) | Etoposide | 0.494 | 0.01744 | 0.4946 |
| DAOY | CFI-400945 (10nM) | Etoposide | 0.800 | 0.00374 | NS |
NS - not significant.
*IC50 value for combination vs. IC50 control.